File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Telbivudine: a new treatment option in the management of chronic hepatitis B

TitleTelbivudine: a new treatment option in the management of chronic hepatitis B
Authors
KeywordsMedical sciences
Communicable diseases
Issue Date2006
PublisherMedknow Publications Pvt Ltd. The Journal's web site is located at http://www.hepatitisbannual.org
Citation
Hepatitis B Annual, 2006, v. 3 n. 1, p. 14-34 How to Cite?
AbstractChronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma. Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir dipivoxil, entecavir and recently telbivudine. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, the search for new agents and treatment strategies continues. Telbivudine is the latest approved anti-HBV agent; it is an orally administered nucleoside analog that selectively inhibits HBV replication. It has demonstrated potent activity against HBV in clinical studies, with good tolerance, lack of mitochondrial toxicity and no dose-limiting side effects. This review focuses on telbivudine, the latest oral antiviral agent for the treatment of chronic hepatitis B.
Persistent Identifierhttp://hdl.handle.net/10722/57528
ISSN
2013 SCImago Journal Rankings: 0.103

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2010-04-12T01:39:11Z-
dc.date.available2010-04-12T01:39:11Z-
dc.date.issued2006en_HK
dc.identifier.citationHepatitis B Annual, 2006, v. 3 n. 1, p. 14-34en_HK
dc.identifier.issn0972-9747en_HK
dc.identifier.urihttp://hdl.handle.net/10722/57528-
dc.description.abstractChronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma. Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir dipivoxil, entecavir and recently telbivudine. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, the search for new agents and treatment strategies continues. Telbivudine is the latest approved anti-HBV agent; it is an orally administered nucleoside analog that selectively inhibits HBV replication. It has demonstrated potent activity against HBV in clinical studies, with good tolerance, lack of mitochondrial toxicity and no dose-limiting side effects. This review focuses on telbivudine, the latest oral antiviral agent for the treatment of chronic hepatitis B.en_HK
dc.languageengen_HK
dc.publisherMedknow Publications Pvt Ltd. The Journal's web site is located at http://www.hepatitisbannual.orgen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsHepatitis B Annual. Copyright © Medknow Publications Pvt Ltd.en_HK
dc.subjectMedical sciencesen_HK
dc.subjectCommunicable diseasesen_HK
dc.titleTelbivudine: a new treatment option in the management of chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0972-9747&volume=3&issue=1&spage=14&epage=34&date=2006&atitle=Telbivudine:+a+new+treatment+option+in+the+management+of+chronic+hepatitis+Ben_HK
dc.identifier.emailFung, J: jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.hkuros132174-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats